Dr. Barocas on Adjuvant Sunitinib in Renal Cell Carcinoma

Video

Daniel A. Barocas, MD, MPH, FACS, discusses adjuvant TKI therapy in patients with renal cell carcinoma at high risk of recurrence following cytoreductive nephrectomy.

Daniel A. Barocas, MD, MPH, FACS, an associate professor in the Department of Urology at Vanderbilt University Medical Center, discusses adjuvant TKI therapy in patients with renal cell carcinoma (RCC) at high risk of recurrence following cytoreductive nephrectomy.

The most compelling data in favor of adjuvant TKI therapy in RCC comes from the phase III S-TRAC study, which showed a disease-free survival advantage for sunitinib (Sutent) compared with placebo; however, those results are competing with other studies that show no advantage for sunitinib, explains Barocas.

The S-TRAC study showed some adverse events (AEs) in the sunitinib arm compared with the placebo arm. Key AEs occurred a median of 1 month after the start of treatment and resolved within a median 3.5 weeks. Data showed that 40.6% of grade 1/2 AEs led to discontinuation and 87.2% of AEs were resolved or were resolving by 28 days after the last treatment. Barocas suggests using adjuvant sunitinib for patients who are motivated to prevent disease recurrence.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Related Content
© 2025 MJH Life Sciences

All rights reserved.